XTX 401
Alternative Names: XTX-401Latest Information Update: 28 Jun 2025
At a glance
- Originator Xilio Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins
- Mechanism of Action Interleukin 15 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 03 May 2022 Xilio Therapeutics anticipates IND enabling studies for Cancer (Xilio Therapeutics Form 10K, April 2022)
- 28 Apr 2022 Xilio Therapeutics has patents pending for different masked IL-15 constructs and sequences, including XTX 401 as PCT and Taiwan applications (Xilio Therapeutics Form 10K, April 2022)